REGENXBIO

Biotechnology Research • Rockville, Maryland, United States • 201-500 Employees

Company overview

Headquarters	9804 Medical Center Dr, Rockville, Maryland 20850, US
Phone number	+12405528181
Website	regenxbio.com
NAICS	541714
SIC	873
Keywords	Biotechnology, Gene Therapy, Biopharmaceuticals
Founded	2008
Employees	201-500
Socials

Key Contacts at REGENXBIO

Paul Oyefesobi

Associate Director, Pricing And Market Access

Vivian Fernandez

Executive Director, Patient Advocacy

Rushi Shah

Senior Director Medical Affairs

Tom Bujold

Sr. Director Quality Control

Tracy Merrell

Senior Director, Hr & Business Partner

Maryam Mokhtarzadeh

Senior Director, Regulatory Strategy

Kim Irwin-Pack

Executive Director Drug Delivery & Training

Matt Abend

Director - Internal Audit

Toni Guiriba

Associate Director, Corporate Strategy

Matt Stone

Director, Commercial Supply

REGENXBIO Email Formats

REGENXBIO uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@regenxbio.com), used 69.3% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@regenxbio.com	69.3%
{first name}{last name}	johndoe@regenxbio.com	23.2%
{last name}{last name}	doedoe@regenxbio.com	6.4%

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.

REGENXBIO revenue & valuation

Annual revenue	$155,800,000
Revenue per employee	$404,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$498,600,000
Total funding	$520,300,000

Employees by Management Level

Total employees: 201-500

Seniority

Employees

Entry

Director

Manager

Employees by Department

REGENXBIO has 170 employees across 15 departments.

Departments

Number of employees

Funding Data

Explore REGENXBIO's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2021-02-06	14	$230,300,000
2024-04-06	14	$140,000,000
2025-06-19	16	$150,000,000

Funding Insights

$520,300,000

Total funding amount

$150,000,000

Most recent funding amount

Number of funding rounds

REGENXBIO Tech Stack

Discover the technologies and tools that power REGENXBIO's digital infrastructure, from frameworks to analytics platforms.

Modernizr

JavaScript libraries

reCAPTCHA

Security

Windows Server

Operating systems

Vimeo

Video players

Cookie Control

Cookie compliance

Microsoft 365

jQuery

JavaScript libraries

HSTS

Security

Google Analytics

Analytics

Microsoft ASP.NET

Web frameworks

Google Tag Manager

Tag managers

Cookiebot

Cookie compliance

Frequently asked questions

REGENXBIO is located in Rockville, Maryland, US.

You can reach REGENXBIO at +12405528181.

REGENXBIO was founded in 2008, making it 18 years old. The company has established itself as a significant player in its industry over this time.

REGENXBIO has approximately 201-500 employees. The company continues to grow its workforce to support its business operations and expansion.

REGENXBIO has raised a total of $520,300,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.